(BNR) Brenntag SE - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000A1DAHH0
Stock: Chemicals, Ingredients, Additives, Solvents
Total Rating 30
Risk 88
Buy Signal -0.32
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.70% |
| Yield on Cost 5y | 3.67% |
| Yield CAGR 5y | 11.68% |
| Payout Consistency | 99.7% |
| Payout Ratio | 91.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.4% |
| Relative Tail Risk | -4.12% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.25 |
| Alpha | -12.79 |
| Character TTM | |
|---|---|
| Beta | 0.204 |
| Beta Downside | 0.443 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.34% |
| CAGR/Max DD | -0.13 |
Description: BNR Brenntag SE January 07, 2026
Brenntag SE (XETRA:BNR) is the world’s largest independent chemical distributor, operating in 70+ countries and serving key markets such as nutrition, pharma, beauty, water treatment, and industrial coatings. The business is split into two segments-Brenntag Essentials (commodity chemicals) and Brenntag Specialties (high-value, customized formulations)-and offers end-to-end services including just-in-time delivery, blending, inventory management, regulatory compliance, and digital sales platforms.
In FY 2023 Brenntag generated €15.5 billion of revenue with an adjusted EBITDA margin of roughly 7.5%, reflecting strong demand for specialty chemicals and the company’s efficient logistics model. Growth is underpinned by three macro drivers: (1) rising global consumption of specialty chemicals in pharma and nutrition, (2) supply-chain reshoring trends that favor local distributors, and (3) increasing price volatility of feedstock, which rewards firms with diversified sourcing and inventory-management capabilities.
For a deeper quantitative view of Brenntag’s valuation metrics, the ValueRay platform offers a granular, data-driven dashboard worth checking.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 417.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.28 > 1.0 |
| NWC/Revenue: 13.62% < 20% (prev 10.12%; Δ 3.49% < -1%) |
| CFO/TA 0.09 > 3% & CFO 989.4m > Net Income 417.9m |
| Net Debt (-57.8m) to EBITDA (1.30b): -0.04 < 3 |
| Current Ratio: 1.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (145.0m) vs 12m ago 0.59% < -2% |
| Gross Margin: 25.14% > 18% (prev 0.19%; Δ 2495 % > 0.5%) |
| Asset Turnover: 143.1% > 50% (prev 144.7%; Δ -1.60% > 0%) |
| Interest Coverage Ratio: 4.91 > 6 (EBITDA TTM 1.30b / Interest Expense TTM 159.0m) |
Altman Z'' 3.50
| A: 0.20 (Total Current Assets 4.62b - Total Current Liabilities 2.49b) / Total Assets 10.68b |
| B: 0.34 (Retained Earnings 3.67b / Total Assets 10.68b) |
| C: 0.07 (EBIT TTM 780.4m / Avg Total Assets 10.94b) |
| D: 0.56 (Book Value of Equity 3.56b / Total Liabilities 6.34b) |
| Altman-Z'' Score: 3.50 = A |
Beneish M -3.30
| DSRI: 0.98 (Receivables 2.45b/2.58b, Revenue 15.65b/16.19b) |
| GMI: 0.76 (GM 25.14% / 19.23%) |
| AQI: 1.05 (AQ_t 0.37 / AQ_t-1 0.35) |
| SGI: 0.97 (Revenue 15.65b / 16.19b) |
| TATA: -0.05 (NI 417.9m - CFO 989.4m) / TA 10.68b) |
| Beneish M-Score: -3.30 (Cap -4..+1) = AA |
What is the price of BNR shares?
As of February 09, 2026, the stock is trading at EUR 55.56 with a total of 253,880 shares traded.
Over the past week, the price has changed by +9.59%, over one month by +12.86%, over three months by +19.61% and over the past year by -7.06%.
Over the past week, the price has changed by +9.59%, over one month by +12.86%, over three months by +19.61% and over the past year by -7.06%.
Is BNR a buy, sell or hold?
Brenntag SE has no consensus analysts rating.
What are the forecasts/targets for the BNR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50.9 | -8.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 60.7 | 9.3% |
BNR Fundamental Data Overview February 09, 2026
Market Cap USD = 9.49b (8.02b EUR * 1.1827 EUR.USD)
P/E Trailing = 19.1586
P/E Forward = 10.8578
P/S = 0.5126
P/B = 1.8585
Revenue TTM = 15.65b EUR
EBIT TTM = 780.4m EUR
EBITDA TTM = 1.30b EUR
Long Term Debt = 2.59b EUR (from longTermDebt, last quarter)
Short Term Debt = 120.5m EUR (from shortTermDebt, last quarter)
Debt = 533.7m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -57.8m EUR (from netDebt column, last quarter)
Enterprise Value = 7.96b EUR (8.02b + Debt 533.7m - CCE 591.5m)
Interest Coverage Ratio = 4.91 (Ebit TTM 780.4m / Interest Expense TTM 159.0m)
EV/FCF = 11.86x (Enterprise Value 7.96b / FCF TTM 671.3m)
FCF Yield = 8.43% (FCF TTM 671.3m / Enterprise Value 7.96b)
FCF Margin = 4.29% (FCF TTM 671.3m / Revenue TTM 15.65b)
Net Margin = 2.67% (Net Income TTM 417.9m / Revenue TTM 15.65b)
Gross Margin = 25.14% ((Revenue TTM 15.65b - Cost of Revenue TTM 11.71b) / Revenue TTM)
Gross Margin QoQ = 25.47% (prev 25.18%)
Tobins Q-Ratio = 0.75 (Enterprise Value 7.96b / Total Assets 10.68b)
Interest Expense / Debt = 6.86% (Interest Expense 36.6m / Debt 533.7m)
Taxrate = 36.99% (67.1m / 181.4m)
NOPAT = 491.7m (EBIT 780.4m * (1 - 36.99%))
Current Ratio = 1.86 (Total Current Assets 4.62b / Total Current Liabilities 2.49b)
Debt / Equity = 0.12 (Debt 533.7m / totalStockholderEquity, last quarter 4.32b)
Debt / EBITDA = -0.04 (Net Debt -57.8m / EBITDA 1.30b)
Debt / FCF = -0.09 (Net Debt -57.8m / FCF TTM 671.3m)
Total Stockholder Equity = 4.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.82% (Net Income 417.9m / Total Assets 10.68b)
RoE = 9.30% (Net Income TTM 417.9m / Total Stockholder Equity 4.49b)
RoCE = 11.02% (EBIT 780.4m / Capital Employed (Equity 4.49b + L.T.Debt 2.59b))
RoIC = 9.49% (NOPAT 491.7m / Invested Capital 5.18b)
WACC = 6.52% (E(8.02b)/V(8.56b) * Re(6.67%) + D(533.7m)/V(8.56b) * Rd(6.86%) * (1-Tc(0.37)))
Discount Rate = 6.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.28%
[DCF Debug] Terminal Value 83.94% ; FCFF base≈671.6m ; Y1≈680.6m ; Y5≈740.1m
Fair Price DCF = 126.8 (EV 18.26b - Net Debt -57.8m = Equity 18.31b / Shares 144.4m; r=6.52% [WACC]; 5y FCF grow 1.03% → 2.90% )
EPS Correlation: -73.61 | EPS CAGR: -51.96% | SUE: -4.0 | # QB: 0
Revenue Correlation: -71.89 | Revenue CAGR: -2.20% | SUE: -0.25 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.85 | Chg30d=-0.240 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=3.74 | Chg30d=-0.203 | Revisions Net=-7 | Growth EPS=+8.6% | Growth Revenue=-0.8%
P/E Trailing = 19.1586
P/E Forward = 10.8578
P/S = 0.5126
P/B = 1.8585
Revenue TTM = 15.65b EUR
EBIT TTM = 780.4m EUR
EBITDA TTM = 1.30b EUR
Long Term Debt = 2.59b EUR (from longTermDebt, last quarter)
Short Term Debt = 120.5m EUR (from shortTermDebt, last quarter)
Debt = 533.7m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -57.8m EUR (from netDebt column, last quarter)
Enterprise Value = 7.96b EUR (8.02b + Debt 533.7m - CCE 591.5m)
Interest Coverage Ratio = 4.91 (Ebit TTM 780.4m / Interest Expense TTM 159.0m)
EV/FCF = 11.86x (Enterprise Value 7.96b / FCF TTM 671.3m)
FCF Yield = 8.43% (FCF TTM 671.3m / Enterprise Value 7.96b)
FCF Margin = 4.29% (FCF TTM 671.3m / Revenue TTM 15.65b)
Net Margin = 2.67% (Net Income TTM 417.9m / Revenue TTM 15.65b)
Gross Margin = 25.14% ((Revenue TTM 15.65b - Cost of Revenue TTM 11.71b) / Revenue TTM)
Gross Margin QoQ = 25.47% (prev 25.18%)
Tobins Q-Ratio = 0.75 (Enterprise Value 7.96b / Total Assets 10.68b)
Interest Expense / Debt = 6.86% (Interest Expense 36.6m / Debt 533.7m)
Taxrate = 36.99% (67.1m / 181.4m)
NOPAT = 491.7m (EBIT 780.4m * (1 - 36.99%))
Current Ratio = 1.86 (Total Current Assets 4.62b / Total Current Liabilities 2.49b)
Debt / Equity = 0.12 (Debt 533.7m / totalStockholderEquity, last quarter 4.32b)
Debt / EBITDA = -0.04 (Net Debt -57.8m / EBITDA 1.30b)
Debt / FCF = -0.09 (Net Debt -57.8m / FCF TTM 671.3m)
Total Stockholder Equity = 4.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.82% (Net Income 417.9m / Total Assets 10.68b)
RoE = 9.30% (Net Income TTM 417.9m / Total Stockholder Equity 4.49b)
RoCE = 11.02% (EBIT 780.4m / Capital Employed (Equity 4.49b + L.T.Debt 2.59b))
RoIC = 9.49% (NOPAT 491.7m / Invested Capital 5.18b)
WACC = 6.52% (E(8.02b)/V(8.56b) * Re(6.67%) + D(533.7m)/V(8.56b) * Rd(6.86%) * (1-Tc(0.37)))
Discount Rate = 6.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.28%
[DCF Debug] Terminal Value 83.94% ; FCFF base≈671.6m ; Y1≈680.6m ; Y5≈740.1m
Fair Price DCF = 126.8 (EV 18.26b - Net Debt -57.8m = Equity 18.31b / Shares 144.4m; r=6.52% [WACC]; 5y FCF grow 1.03% → 2.90% )
EPS Correlation: -73.61 | EPS CAGR: -51.96% | SUE: -4.0 | # QB: 0
Revenue Correlation: -71.89 | Revenue CAGR: -2.20% | SUE: -0.25 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.85 | Chg30d=-0.240 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=3.74 | Chg30d=-0.203 | Revisions Net=-7 | Growth EPS=+8.6% | Growth Revenue=-0.8%